A new biotechnology company that focuses on precision therapies for kidney disease has been launched by the health care venture capitalist firm Third Rock Ventures LLC. Goldfinch Bio, which aims to target the molecular basis of progressive kidney diseases, was launched with $55 million in Series A financing.
“Recent discoveries have provided groundbreaking insights into the biological mechanisms linked to kidney disease, and Goldfinch has assembled an integrated product engine to enhance this foundational knowledge and rapidly translate new discoveries into novel treatments for patients,” Third Rock Ventures said in a press release.
The new company will initially focus on indications where there is a known genetic component, including focal segmental glomerulosclerosis (FSGS) and polycystic kidney disease (PKD), two conditions for which there are no FDA-approved therapies. Beyond these orphan indications, the company said it will also apply a molecular understanding of disease mechanisms to identify and treat relevant subgroups among the broader population of patients with chronic kidney disease
Goldfinch has developed a product engine that integrates genetic, genomic and biological tools to identify and validate novel drug targets and inform treatment strategies focused on molecularly defined patient groups. The company said it will use a comprehensive patient registry designed to collect and integrate genomic and deep phenotypic data, empowering the discovery of molecular drivers of kidney disease.
The company is led by the following team of scientists and clinicians:
- Senior Vice President of Biology: Company co-founder Peter Mundel, MD, formerly on the faculty at Harvard Medical School
- Senior Vice President of Drug Discovery: Jean-Christophe Harmange, PhD
- Interim Chief Medical Officer: Phil Reilly, MD, JD, clinical geneticist and Third Rock venture partner.
- Interim Chief Operating Officer: Third Rock partner Neil Exter
- Chief Executive Officer: Abbie Celniker, PhD, partner at Third Rock Ventures
“Current treatment options for patients with progressive kidney disease are often off-label, non-specific, and carry significant toxicities,” said Celniker. “By building on recent breakthroughs from our founders to better understand the molecular processes of kidney disease, we see a unique opportunity to spur a renaissance in the discovery and development of new therapies to treat the underlying causes of disease. To accomplish this, Goldfinch has brought together the leading scientists, clinicians, and drug hunters behind a common goal to create the first precision therapies for patients with kidney disease.”